Engineered T cells for cancer treatment.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24239105.
- Also identified by DOI 10.1016/j.jcyt.2013.10.002 and PMC identifier 4013208.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Adoptively transferred T cells have the capacity to traffic to distant tumor sites, infiltrate fibrotic tissue and kill antigen-expressing tumor cells. Various groups have investigated different genetic engineering strategies designed to enhance tumor specificity, increase T cell potency, improve proliferation, persistence or migratory capacity and increase safety. This review focuses on recent developments in T cell engineering, discusses the clinical application of these engineered cell products and outlines future prospects for this therapeutic modality.
Medical subject headings
- Cell Engineering
- Neoplasms
- Recombinant Fusion Proteins
- T-Lymphocytes